<DOC>
	<DOCNO>NCT00864773</DOCNO>
	<brief_summary>The pathophysiology central serous chorioretinopathy remain controversial . traditional treatment laser photocoagulation photodynamic therapy.Recently Bevacizumab ( Avastin , Genetech ) , antibody vascular endothelial growth factor ( VEGF ) , know antipermeability property therefore may theoretically reverse change see central serous chorioretinopathy . The aim study To investigate concentration growth factor inflammatory cytokine report effect therapy bevacizumab eye central serous chorioretinopathy</brief_summary>
	<brief_title>The Effect Therapy With Bevacizumab Chronic Central Serous Chorioretinopathy</brief_title>
	<detailed_description />
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients diagnosis central serous chorioretinopathy Idiopathic neurosensory retinal elevation demonstrate optical coherent tomography Presence focal leak level RPE fluorescein angiography Known side effect systemic bevacizumab administration Have significant cardiovascular thromboembolic history pregnant</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>